Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Objectives: Esophageal adenosquamous carcinoma (ASC) is a rare tumor with characteristics of adenocarcinoma (AC) and squamous cell carcinoma (SCC), the two most common esophageal cancers. Its behavior is aggressive but poorly understood. Using the National Cancer Database (NCDB), the clinical features and overall survival of ASC were compared with AC and SCC. Methods: The NCDB was queried for patients with esophageal ASC, AC, and SCC. Univariate association of histology with patient characteristics and overall survival were analyzed and socioeconomic characteristics were balanced. Results: Clinical M stage was 0 in a significantly lower proportion of ASC (69.0%) than in AC (70.9%) or SCC (75.6%) ( p < 0.001). Median survival was lower in patients with ASC (9.6 months) than with AC (13.5) or SCC (9.7) and 2-year OS was lower in patients with ASC (23.8%) than with AC (34.6%) or SCC (26.5%) ( p < 0.001). The OS hazard ratio for ASC was 1.14 when compared to AC (95% CI = 1.016-1.267, p = 0.025) and 1.10 when compared to SCC, but the latter was not significant (95% CI = 0.980-1.222, p = 0.111). Conclusion: ASC is a rare tumor among esophageal carcinomas with a greater burden of metastatic disease than AC or SCC and worse OS than AC.

Related collections

Author and article information

Journal

Journal ID (publisher-id): OCL

Journal ID (nlm-ta): Oncology

Journal ID (doi): 10.1159/issn.0030-2414

Title: Oncology

Publisher: S. Karger AG

ISSN (Print): 0030-2414

ISSN (Electronic): 1423-0232

Publication date Subscription-year: 2017

Publication date (Print): October 2017

Publication date (Electronic): 24 August 2017

Volume: 93

Issue: 5

Pages: 336-342

Affiliations

^aDepartment of Internal Medicine, Emory University School of Medicine, ^bDepartment of Biostatistics and Bioinformatics: Rollins School of Public Health of Emory University, ^cBioinformatics and Biostatistics Shared Resource, ^dDepartment of Hematology and Medical Oncology, and ^eDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, ^fDivision of Digestive Disease, ^gDepartment of Surgery, ^hDepartment of Pathology & Laboratory Medicine, and ⁱDepartment of Otolaryngology, Emory University School of Medicine, Atlanta, GA, USA

Author notes

*Dr. Nabil F. Saba, Winship Cancer Institute of Emory University, 1365 Clifton Road, Atlanta, GA 30322-1013 (USA), E-Mail nfsaba@emory.edu

Article

Publisher ID: 466699 Other ID: Oncology 2017;93:336-342

DOI: 10.1159/000466699

PubMed ID: 28848104

SO-VID: a802869b-f6f0-4146-8139-7e80d0d27282

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 10 October 2016

Date accepted : 23 February 2017

Page count

Figures: 1, Tables: 1, References: 27, Pages: 7

Comments

Comment on this article

scite_

Cited by 8

See all cited by

Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

Submit here before July 31, 2024